Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studies

医学 内科学 不利影响 入射(几何) 疾病 百时美 胃肠病学 光学 物理
作者
Xenofon Baraliakos,Atul Deodhar,Désirée M F M van der Heijde,Filip E Van den Bosch,Marina Magrey,Walter P. Maksymowych,Tetsuya Tomita,Huji Xu,Ute Massow,Tom Vaux,Chetan Prajapati,Myriam Manente,Alexander Marten,Lianne S. Gensler
出处
期刊:Rheumatology [Oxford University Press]
卷期号:64 (6): 3534-3546 被引量:23
标识
DOI:10.1093/rheumatology/keaf009
摘要

OBJECTIVES: Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A, previously demonstrated efficacy and was well tolerated to 1 year in patients with non-radiographic (nr-) and radiographic (r-) axial spondyloarthritis (axSpA). Here, we report bimekizumab safety and efficacy to 2 years. METHODS: Patients completing week 52 in the phase 3 studies BE MOBILE 1 (nr-axSpA; NCT03928704) and 2 (r-axSpA; NCT03928743) were eligible for an ongoing open-label extension (OLE; NCT04436640). All OLE patients received subcutaneous bimekizumab 160 mg every 4 weeks. Safety outcomes for patients who received ≥1 bimekizumab dose, and efficacy outcomes for all randomized patients, are reported to week 104. RESULTS: In the OLE (weeks 52 - 104), 70.8% (367/518) of patients reported ≥1 treatment-emergent adverse event (TEAE). Most frequent TEAEs [exposure-adjusted incidence rate per 100 patient-years (EAIR/100PY)] were SARS-CoV-2 (COVID-19) infection (25.2), nasopharyngitis (11.0) and oral candidiasis (5.4). Fungal infection EAIR/100PY was 11.8 (majority Candida infections: 6.8; most mild/moderate, none serious/systemic). Inflammatory bowel disease and uveitis rates were low; no major adverse cardiovascular events or deaths occurred. TEAE incidence rate was generally similar across weeks 0 - 52 and 52 - 104.At week 104, >50% of randomized patients (N = 586) achieved Assessment of SpondyloArthritis international Society 40% response (ASAS40); ∼60% achieved Axial Spondyloarthritis Disease Activity Score (ASDAS) low disease activity (<2.1) and >30% achieved ASDAS inactive disease (<1.3). Bimekizumab demonstrated sustained suppression of MRI inflammation at week 104, with >57% of patients achieving MRI remission. CONCLUSIONS: The safety profile of bimekizumab remained consistent with prior reports, with no new safety signals identified. 1-year efficacy was sustained to 2 years across patients with nr-axSpA and r-axSpA.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
眠龙完成签到 ,获得积分10
刚刚
猪猪侠完成签到,获得积分10
1秒前
1秒前
1秒前
英俊的铭的应助被xxx采纳,获得10
2秒前
水煮电吹风的应助被叶95采纳,获得10
2秒前
ylfs完成签到,获得积分10
2秒前
3秒前
bobo完成签到,获得积分10
4秒前
小艾同学发布了新的文献求助10
4秒前
see发布了新的文献求助10
5秒前
在水一方的应助被LILILILI采纳,获得30
6秒前
嘤嘤嘤完成签到,获得积分10
6秒前
6秒前
999完成签到,获得积分10
6秒前
123完成签到 ,获得积分10
7秒前
香蕉觅云的应助被祥子的骆驼采纳,获得10
8秒前
。。。完成签到,获得积分0
10秒前
自然思烟完成签到,获得积分10
11秒前
bbb发布了新的文献求助10
13秒前
冷酷以山发布了新的文献求助10
13秒前
anders完成签到 ,获得积分10
15秒前
进化又不带我完成签到 ,获得积分10
15秒前
16秒前
科研通AI6.3的应助被z啧啧啧采纳,获得10
16秒前
17秒前
昏睡的帆布鞋完成签到 ,获得积分10
18秒前
xwx发布了新的文献求助10
20秒前
沉默尔冬完成签到,获得积分10
20秒前
我是老大的应助被李老头采纳,获得10
20秒前
21秒前
GIN完成签到,获得积分10
21秒前
璇璇完成签到 ,获得积分10
22秒前
23秒前
无花果的应助被科研通管家采纳,获得30
23秒前
深情安青的应助被科研通管家采纳,获得10
23秒前
Owen的应助被科研通管家采纳,获得10
23秒前
aqqq的应助被科研通管家采纳,获得20
23秒前
aqqq的应助被科研通管家采纳,获得10
23秒前
田様的应助被科研通管家采纳,获得10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181658
求助须知:如何正确求助?哪些是违规求助? 9571454
关于积分的说明 21818081
捐赠科研通 7777987
什么是DOI,文献DOI怎么找? 3433508
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479568